A GlaxoSmithKline drug is being trialled as part of a programme to increase the number of treatments available to UK cancer patients.
Cancer Research UK is sponsoring tests of the aurora kinase inhibitor 1070916A at the Institute of Oncology at St James’s University Hospital and the Experimental Cancer Medicine Centre in London.
It is the first patient-ready drug to enter Cancer Research UK’s Clinical Development Partnerships (CDP) programme. If it is successful, further trials may follow.
Says Dr Victoria John, head of clinical partnerships: “This deal brings our CDP portfolio to three and the total number of new drugs in our early preclinical and clinical pipeline to over 40, something we believe is testament to the specialist skills and capability of our drug-development team.”
The programme, which enables companies to retain rights to the drug throughout the development programme, is an alternative to traditional outlicensing.
Copyright Press Association 2009